Clinic Roundup

• Genmab A/S, of Copenhagen, Denmark, submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL). Patients in the study will receive ofatumumab plus chemotherapy or Rituxan (rituximab, Biogen Idec Inc. and Roche AG) plus chemotherapy.